Today: 30 June 2026
ASML stock hits record high as market value tops $500 billion after TSMC blowout
15 January 2026
1 min read

ASML stock hits record high as market value tops $500 billion after TSMC blowout

AMSTERDAM, January 15, 2026, 10:54 CET — Regular session

  • ASML shares hit a record high of 1,167 euros, pushing the chip equipment maker’s market value beyond $500 billion
  • TSMC’s robust earnings sparked a wider semiconductor rally across Europe
  • Investors are eyeing ASML’s January 28 earnings for updates on bookings and guidance

ASML Holding’s shares surged to a new all-time peak on Thursday, pushing the Dutch chip equipment maker’s market cap beyond $500 billion. That keeps ASML firmly in the lead as Europe’s most valuable publicly traded company.

This is crucial since ASML occupies the bottleneck in advanced chip manufacturing. When major chipmakers mention increased demand and ramped-up spending, the ripple usually hits their equipment orders first.

This time, it wasn’t an ASML update that set things off. Instead, Taiwan Semiconductor Manufacturing Co’s results brought some clarity to the ongoing debate: is AI demand enough to push chipmakers into ramping up factory investments again?

ASML shares climbed about 5% in Amsterdam, hitting 1,167 euros and pushing the company’s market value to roughly 443 billion euros ($515 billion) by late morning. This surge drove the stock deeper into record territory.

The broader market held steady as well. European tech shares surged, driven by the STOXX Europe technology index’s strong climb. Investors shifted focus back to chip-related stocks following TSMC’s latest update.

In Taipei, TSMC reported a 35% jump in fourth-quarter net profit, hitting a record high, and projected capital expenditures between $52 billion and $56 billion in 2026. The company pointed to strong demand fueled by the so-called “AI mega trend.” CEO C.C. Wei sounded cautious, saying, “We’re also very nervous about it,” during a press briefing. Ben Barringer, head of technology research at Quilter Cheviot, called the results “a very positive start,” noting TSMC’s position as the go-to manufacturer for top chip designers. Reuters

ASML’s outlook is clear-cut. With TSMC as a major client, the spending rhythm at foundries and memory producers directly influences demand for ASML’s cutting-edge equipment.

ASML manufactures lithography machines, including extreme ultraviolet (EUV) systems—crucial for printing the smallest circuit patterns on silicon wafers used in advanced chips. Tool orders and service work usually benefit from ongoing investment cycles in both logic chips and high-end memory.

The situation can change quickly. Should demand tied to AI slow down or customers delay factory construction, equipment orders could drop sharply. With sky-high valuations in the sector, there’s minimal room for error. On top of that, export rules and geopolitical tensions continue to pose major risks for European chip-tool firms exposed to China.

ASML’s next major event is its quarterly earnings release. The company plans to report fourth-quarter and full-year 2025 results on January 28. Investors will zero in on bookings, margins, and any changes to the 2026 guidance.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge
Previous Story

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls
Next Story

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls

Go toTop